October 2022

Letter to Investors and Friends

Dear Investors and Friends of Cascade Prodrug Inc,

On behalf of our leadership team, I am pleased to inform you that the FDA has granted the company Orphan Drug Designation [ODD] for CPD 100Li for the treatment of pancreatic cancer.

At a high level this designation provides:

  • Tax credits up to 50% for research and clinical drug testing expenses
  • Eligibility for market exclusivity for 7 years AFTER pre-market approval
  • Waiver of new drug application [NDA] application fee [Approximately worth $2M+]
  • Pediatric Research Equity Act Exemption

In summary, this designation on the part of the FDA clearly supports the direction and focus the company is pursuing under its preclinical development and commercial partnering initiatives.

We thank our investors and friends for their support.

Kind Regards,

Allan Cochrane,
Co-Founder and Managing Director
Cascade Prodrug, Inc.

Apr. 4, 2017

New Drug Delivery System Could Help Fight Tumors

April 4 (UPI) — Researchers at Oregon State University have developed a new cancer-drug delivery system that may help overcome the challenge of treating solid tumors often resistant to treatment.

Carcinomas, a type of cancer that affect the lung, prostate, colon and breast, are solid tumors that contain hypoxic or low oxygen regions that cause slow growth and resistance to drug treatment to shrink or kill the tumor.

The team at Oregon State found a way to use a prodrug, a pharmacologically inactive compound that is metabolized by the body into an active drug, to overcome the hypoxia of carcinoma tumors…

Apr. 3, 2017

New Drug Delivery System Shows Promise For Fighting Solid Tumors

PORTLAND, Ore. – A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.

Carcinomas that affect the breast, lung, prostate and colon are among the solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue.

These solid masses often contain hypoxic regions, where the concentration of oxygen in the tissue is low. Hypoxic cancer cells grow slowly, and that makes them less susceptible to the drugs prescribed to kill or damage them…